Skip to search formSkip to main contentSkip to account menu

BIBW 2992

Known as: BIBW-2992, BIBW2992 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Afatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
The secondary EGF receptor (EGFR) T790M is the most common mechanism of resistance to reversible EGFR-tyrosine kinase inhibitors… 
Review
2012
Review
2012
New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Highly Cited
2012
Highly Cited
2012
Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
Non-small-cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations attains a meaningful response to EGFR… 
Review
2012
Review
2012
Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
The discovery of mutations in the epidermal growth factor receptor (EGFR) has marked a dramatic change in the treatment of lung… 
Highly Cited
2011
Highly Cited
2011
Afatinib (BIBW 2992) development in non-small-cell lung cancer.
Afatinib (BIBW 2992), a novel aniline-quinazoline derivative, irreversibly and equipotently targets the intrinsic kinase activity… 
Highly Cited
2010
Highly Cited
2010
Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor
Most non–small cell lung cancer (NSCLC) tumors with activating mutations of the epidermal growth factor receptor (EGFR) are… 
Review
2010
Review
2010
A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).
7521^ Background: NSCLC patients whose tumors harbor epidermal growth factor receptor EGFR/HER1 mutations represent a unique… 
Highly Cited
2009
Highly Cited
2009
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
Mutations in the HER2 kinase domain have been identified in human clinical lung cancer specimens. Here we demonstrate that… 
2009
2009
Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.
Background: BIBW 2992 (Tovok™*) is a novel, oral, irreversible inhibitor of the epidermal growth factor receptor (EGFR)/human… 
Highly Cited
2007
Highly Cited
2007
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients…
To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of the dual epidermal growth factor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)